Linked Life Data

15207337

Source:http://linkedlifedata.com/resource/pubmed/id/15207337

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-6-21
pubmed:abstractText
Tumors including sarcomas and breast, prostate, and lung carcinomas frequently grow in or metastasize to the skeleton where they can induce significant bone remodeling and cancer pain. To define products that are released from tumors that are involved in the generation and maintenance of bone cancer pain, we focus here on endothelin-1 (ET-1) and endothelin receptors as several tumors including human prostate and breast have been shown to express high levels of ETs and the application of ETs to peripheral nerves can induce pain. Here we show that in a murine osteolytic 2472 sarcoma model of bone cancer pain, the 2472 sarcoma cells express high levels of ET-1, but express low or undetectable levels of endothelin A (ETAR) or B (ETBR) receptors whereas a subpopulation of sensory neurons express the ETAR and non-myelinating Schwann cells express the ETBR. Acute (10 mg/kg, i.p.) or chronic (10 mg/kg/day, p.o.) administration of the ETAR selective antagonist ABT-627 significantly attenuated ongoing and movement-evoked bone cancer pain and chronic administration of ABT-627 reduced several neurochemical indices of peripheral and central sensitization without influencing tumor growth or bone destruction. In contrast, acute treatment (30 mg/kg, i.p.) with the ETBR selective antagonist, A-192621 increased several measures of ongoing and movement evoked pain. As tumor expression and release of ET-1 has been shown to be regulated by the local environment, location specific expression and release of ET-1 by tumor cells may provide insight into the mechanisms that underlie the heterogeneity of bone cancer pain that is frequently observed in humans with multiple skeletal metastases.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0306-4522
pubmed:author
pubmed:copyrightInfo
Copyright 2004 IBRO
pubmed:issnType
Print
pubmed:volume
126
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1043-52
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:15207337-Analysis of Variance, pubmed-meshheading:15207337-Animals, pubmed-meshheading:15207337-Behavior, Animal, pubmed-meshheading:15207337-Bone Neoplasms, pubmed-meshheading:15207337-Calcitonin Gene-Related Peptide, pubmed-meshheading:15207337-Disease Models, Animal, pubmed-meshheading:15207337-Dynorphins, pubmed-meshheading:15207337-Endothelin-1, pubmed-meshheading:15207337-Ganglia, Spinal, pubmed-meshheading:15207337-Gene Expression Regulation, Neoplastic, pubmed-meshheading:15207337-Glial Fibrillary Acidic Protein, pubmed-meshheading:15207337-Immunohistochemistry, pubmed-meshheading:15207337-Male, pubmed-meshheading:15207337-Mice, pubmed-meshheading:15207337-Mice, Inbred Strains, pubmed-meshheading:15207337-Pain, pubmed-meshheading:15207337-Pain Measurement, pubmed-meshheading:15207337-Pyrrolidines, pubmed-meshheading:15207337-Receptors, Endothelin, pubmed-meshheading:15207337-Sarcoma, pubmed-meshheading:15207337-Sciatic Nerve, pubmed-meshheading:15207337-Time Factors
pubmed:year
2004
pubmed:articleTitle
Endothelin and the tumorigenic component of bone cancer pain.
pubmed:affiliation
Neurosystems Center and Department of Preventive Sciences, 18-208 Moos Tower, University of Minnesota, 515 Delaware Street Southeast, Minneapolis, MN 55455, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't